Mottahedin A, Blondel S, Ek J, Leverin AL, Svedin P, Hagberg H, et al
Children with PraderWilli syndrome exhibit more evident meal-induced responses in plasma ghrelin and peptide YY levels than obese and lean children
Earlier this year (April 2025), Lilly reported positive Phase III results for orforglipron, an oral small-molecule (non-peptide) GLP-1 receptor agonist, for treating Type 2 diabetes and obesity
By slowing digestion, this medication helps you feel full for longer, reduces cravings, and decreases overall hunger levels
The 12mg weekly arm produced a 24.2% mean body weight reduction over 48 weeks, with 26% of participants achieving at least 30% total body weight loss a threshold previously unattained by any pharmacological intervention in a clinical trial setting
By modulating the inflammatory response, TB-500 may contribute to a more favorable healing environment